Format

Send to

Choose Destination
J Hematol Oncol. 2018 Mar 14;11(1):38. doi: 10.1186/s13045-018-0587-3.

Correction to: The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.

Author information

1
Laboratory of Radiobiology, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy. claudio.festuccia@univaq.it.
2
Laboratory of Radiobiology, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy.
3
Division of Radiotherapy, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy.
4
Division of Neurosciences, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy.
5
Division of Applied Biology, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy.
6
Division of Human Anatomy, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy.
7
Laboratory of Applied Biology, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
8
Division of Radiotherapy, Department of Experimental Medicine, University of Rome "La Sapienza", Rome, Italy.
9
Northlake International LLC, Pleasanton, CA, USA.
10
Mundipharma-EDO GmbH, Basel, Switzerland.

Abstract

The original article [1] contained an error whereby Fig. 4 displayed incorrect magnification scales.

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center